2. Search Result
Search Result
Results for "

platelet-rich plasma

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0074
    GPRP
    3 Publications Verification

    Gly-Pro-Arg-Pro; Pefa 6003

    		 Thrombin Cardiovascular Disease
    GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .
    GPRP
  • HY-N1775
    3',4'-Dihydroxyacetophenone

    3,4-DHAP

    		 Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC50 of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and PARP-1 in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .
    3',4'-Dihydroxyacetophenone
  • HY-128039
    17-Phenyl-ω-trinor-PGE2

    		Prostaglandin Receptor Others
    17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production .
    17-Phenyl-ω-trinor-PGE2
  • HY-P5253
    Octapeptide-2

    		Apoptosis Metabolic Disease
    Octapeptide-2 is a biomimetic peptide that mimics the thymosin-β4 growth factor. Octapeptide-2 can promote hair growth, reduce cell apoptosis, and increase the proliferation of keratinocytes. Octapeptide-2 can be used in the research of hair loss and alopecia areata .
    Octapeptide-2
  • HY-N3228
    Myrianthic acid

    		Others Cardiovascular Disease
    Myrianthic acid is a pentacyclic triterpenoid compound. Myrianthic acid can exist in the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora. Myrianthic acid inhibits adrenaline-induced platelet aggregation, with a IC50 of 46.2 μM for this activity. Myrianthic acid can be used in studies related to thrombosis .
    Myrianthic acid
  • HY-123669
    R-138727

    		P2Y Receptor Drug Metabolite Cardiovascular Disease
    R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC50 of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.
    R-138727
  • HY-135447
    BM-531

    		Prostaglandin Receptor Others
    BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED100 of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED50 of 0.482 μM. BM-531 inhibits high-K +-induced contraction of porcine uterine smooth muscle .
    BM-531
  • HY-Y1094
    [Rh(cod)Cl]2

    Chloro(1,5-cyclooctadiene)rhodium(I) dimer

    		 Biochemical Assay Reagents Cardiovascular Disease
    [Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) is a rhodium (I) organometallic dimer complex. [Rh(cod)Cl]2 can inhibit platelet-activating factor-mediated platelet aggregation with IC50 values of 5.2 and 43.3 μM in washed rabbit platelets and human platelet-rich plasmas. [Rh(cod)Cl]2 also can inhibit thrombin-, ADP (HY-W010918)- and collagen-induced aggregation with IC50 values of 16.7, 162 and 69.8 μM. [Rh(cod)Cl]2 can be used for the research of cardiovascular disease, such as thrombosis .
    [Rh(cod)Cl]2
  • HY-137584
    1a,1b-Dihomo prostaglandin E1

    1a,1b-Dihomo PGE1

    		 Prostaglandin Receptor Cardiovascular Disease
    1a,1b-Dihomo prostaglandin E1 (1a,1b-Dihomo PGE1) is an E1-type prostaglandin. 1a,1b-Dihomo prostaglandin E1 can be used for research on platelet aggregation .
    1a,1b-Dihomo prostaglandin E1
  • HY-163341
    PAR4 antagonist 1

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    PAR4 antagonist 1 (Compound 48) is a protease activated receptor 4 (PAR4) antagonist with an IC50 of 1.8 nM. PAR4 antagonist 1 has an IC50 of 2 nM against γ-thrombin-activated PAR4 in platelet-rich plasma (PRP). PAR4 antagonist 1 can be used in antithrombotic research .
    PAR4 antagonist 1
  • HY-128345
    UDM-001651

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .
    UDM-001651
  • HY-19755
    S-5751

    		Prostaglandin Receptor Inflammation/Immunology
    S-5751 is an orally active prostaglandin DP receptor antagonist. S-5751 inhibits cAMP generation in platelet-rich plasma induced by PGD2 with IC50 0.12 μM. S-5751 has anti-inflammatory activity. S-5751 can be used in asthma research .
    S-5751
  • HY-137591
    13,14-Dihydro-15-keto-PGE1

    		Drug Metabolite Endocrinology
    13,14-Dihydro-15-keto-PGE1 is an inactive metabolite of PGE1. 13, 14-Dihydro-15-Keto-pGE1 inhibited platelet aggregation in ADP-induced human isolated platelet-rich plasma with IC50 14.8 μg/mL .
    13,14-Dihydro-15-keto-PGE1
  • HY-19126
    CL-184005

    		Platelet-activating Factor Receptor (PAFR) Infection Cardiovascular Disease
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
    CL-184005
  • HY-107000
    RIG 200

    		Guanylate Cyclase NO Synthase Cardiovascular Disease
    RIG 200 is an S-nitrosothiol nitric oxide (NO) donor. RIG 200 releases NO through decomposition, activating guanylate cyclase (sGCM) in vascular smooth muscle cells, increasing cGMP levels, and leading to vasodilation. RIG 200 significantly inhibits Collagen (HY-NP003)-induced platelet aggregation in platelet-rich plasma (PRP). RIG 200 may be used in research on antithrombus .
    RIG 200
  • HY-113113
    13,14-Dihydro PGE1

    13,14-Dihydroprostaglandin E1

    		 Endogenous Metabolite Metabolic Disease
    13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
    13,14-Dihydro PGE1
  • HY-108561
    L-670596

    		Prostaglandin Receptor Others
    L-670596 is an orally active and selective thrombsxane A2 receptor/prostaglandin receptor antagonist. L-670596 inhibits arachidonic acid (HY-109590) and U-44069 induced bronchoconstriction in the guinea pig. L-670596 also inhibits the aggregation of human platelet rich plasma induced by U-44069 .
    L-670596
  • HY-113113S
    13,14-Dihydro PGE1-d4

    13,14-Dihydroprostaglandin E1-d4; PGE0-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    13,14-Dihydro PGE1-d4 (13,14-Dihydroprostaglandin E1-d4) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
    13,14-Dihydro PGE1-d4
  • HY-182418
    UR-11353

    		Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    UR-11353 is a selective platelet activating factor (PAF) antagonist with long-lasting activity. UR-11353 inhibits PAF-induced platelet aggregation in rabbit platelet-rich plasma. UR-11353 inhibits PAF-induced hypotension in normotensive rats. UR-11353 protects against PAF-induced mortality in mice .
    UR-11353
  • HY-137288
    17-Phenyl-18,19,20-trinor-PGD2

    17-Phenyl-PGD2

    		 Prostaglandin Receptor Cardiovascular Disease
    17-Phenyl-18,19,20-trinor-PGD2 (17-Phenyl-PGD2) is an analogue of prostaglandin D2 (PGD2; HY-101988). 17-Phenyl-18,19,20-trinor-PGD2 is a potent inhibitor of platelet aggregation caused by aenosine diphosphate (ADP), with the IC50 of 8.4 μM (PGD2 IC50 = 18.6 nM). 17-Phenyl-18,19,20-trinor-PGD2 is a weak agonist of cyclic AMP accumulation .
    17-Phenyl-18,19,20-trinor-PGD2
  • HY-11024
    ADP receptor-IN-1

    		P2Y Receptor Cardiovascular Disease
    ADP receptor-IN-1 (compound 21) is a platelet ADP receptor inhibitor. ADP receptor-IN-1 shows both IC50 values <10 μM at a platelet ADP receptor binding assay and aggregation using a platelet-rich plasma assay .
    ADP receptor-IN-1
  • HY-10312
    UR-12947

    		Integrin Cardiovascular Disease
    UR-12947 is a platelet glycoprotein (GP) IIb-IIIa antagonist. UR-12947 exhibits potent inhibitory activity against platelet aggregation in human platelet-rich plasma, with an IC50 value of 3.5 nM. UR-12947 can be used in the research of arterial thrombotic diseases .
    UR-12947
  • HY-175986
    IP receptor agonist 1

    		Prostaglandin Receptor Inflammation/Immunology
    IP receptor agonist 1 (compound 6c-14S) is an orally active I prostanoid receptor agonist, with an IC50 of 0.15 μM for inhibiting platelet aggregation induced by ADP (HY-W010918,300 μM) in rabbit platelet-rich plasma. IP receptor agonist 1 can be used for study of Pulmonary arterial hypertension .
    IP receptor agonist 1
  • HY-N17941
    19-Anhydro-4-epirotungenic acid

    		Others Cardiovascular Disease
    19-Anhydro-4-epirotungenic acid is a triterpenoid compound that can be isolated from the bark of Ilex rotunda Thunb. 19-Anhydro-4-epirotungenic acid shows no activity against ADP-induced platelet aggregation .
    19-Anhydro-4-epirotungenic acid
  • HY-149310A
    Dim16 hydrochloride

    		PCSK9 HMG-CoA Reductase (HMGCR) Metabolic Disease
    Dim16 hydrochloride is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 hydrochloride disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 hydrochloride can be used in research related to hypercholesterolemia .
    Dim16 hydrochloride
  • HY-N17826
    YM-254891

    		Drug Derivative Bacterial P2Y Receptor Endogenous Metabolite Cardiovascular Disease
    YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation .
    YM-254891
  • HY-182625
    GS-1160-180

    		Platelet-activating Factor Receptor (PAFR) Others Inflammation/Immunology
    GS-1160-180 is a PAF receptor antagonist. GS-1160-180 competes with PAF for receptor binding, with no activity against collagen or adenosine diphosphate-induced platelet aggregation. GS-1160-180 can be used for research on asthma, anaphylactic shock, gastric ulceration, and transplant rejection .
    GS-1160-180
  • HY-183983
    PAR4 antagonist 9

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    PAR4 antagonist 9 is an orally active protease-activated receptor 4 (PAR4) antagonist with an IC50 of 2 nM against human targets. PAR4 antagonist 9 functionally modulates PAR4 and inhibits platelet aggregation. PAR4 antagonist 9 can be used in studies related to arterial thrombosis .
    PAR4 antagonist 9
  • HY-186042
    TPα/β antagonist-1

    		Prostaglandin Receptor Cardiovascular Disease
    TPα/β antagonist-1 is a TXA2 receptor α (TPα) and TPβ antagonist with IC50s of 1.52 nM and 0.79 nM, respectively. TPα/β antagonist-1 inhibits U-46619 (HY-108566)-induced intracellular calcium mobilization, and imhibits platelet aggregation. TPα/β antagonist-1 can be used for the research of cardiovascular disease .
    TPα/β antagonist-1
  • HY-182533
    LN5972

    		CXCR Cardiovascular Disease
    LN5972 is a selective ACKR3 agonist with an EC50 of 3.40 μM, showing higher selectivity for ACKR3 over CXCR4. LN5972 induces β-arrestin recruitment to ACKR3/CXCR7. LN5972 reduces the surface expression of P-selectin. LN5972 is applicable to studies related to platelet-mediated thrombosis .
    LN5972
  • HY-N19876
    WF-5239

    		Endogenous Metabolite Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology
    WF-5239 is a fungal metabolite can be found in Aspergillus fumigatus Fresenius. WF-5239 potently inhibits platelet aggregation. WF-5239 can be used for the research of pulmonary thrombosis .
    WF-5239
  • HY-106830
    Pelrinone

    		Phosphodiesterase (PDE) Cardiovascular Disease
    Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC50 of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na +/K +-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .
    Pelrinone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: